Table 4. IC50 determination of pyrrolopyrimidine EGFR inhibitors against osimertinib resistant EGFR-L858R/T790M/C797S a .
| Compound | EGFR HTRF IC50 [nM] |
| L858R/T790M/C797S | |
| 29a | 354 ± 110 |
| 29b | 406 ± 139 |
| 29c | 110 ± 36 |
| 29d | 803 ± 434 |
| 29e | 768 ± 10 |
| 29f | >20 000 |
| 29g | 555 ± 139 |
| 29h | 356 ± 79 |
| 29i | 249 ± 67 |
| 29j | 22 ± 17 |
| 29k | 243 ± 132 |
| 29l | 2343 ± 952 |
| 19a | 50 ± 19 |
| 19b | 113 ± 47 |
| 19c | 21 ± 7 |
| 19d | 9.4 ± 1.5 |
| 19e | 49 ± 35 |
| 19f | 19 ± 11 |
| 19g | 8.6 ± 3.2 |
| 19h | 8.5 ± 3.7 |
| 19i | 2061 ± 359 |
| Gefitinib | 250 ± 23 |
| Afatinib | 25 ± 17 |
| WZ4002 | 452 ± 189 |
| Rociletinib | 541 ± 119 |
| Osimertinib | 116 ± 15 |
| EGF816 | 398 ± 105 |
| Staurosporine | 1.5 ± 0.0 |
aValues are the mean ± SD of three independent measurements in duplicates.